Drug Profile
ICRF 197
Latest Information Update: 21 Aug 2019
Price :
$50
*
At a glance
- Originator Nonindustrial source
- Developer BTG; Nonindustrial source
- Class Antineoplastics
- Mechanism of Action
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Discontinued Chemotherapy-induced damage
Most Recent Events
- 19 Aug 2019 BTG has been acquired by Boston Scientific Corporation
- 01 Nov 1999 ICRF 197 is available for licensing
- 28 May 1999 New profile